The risk or severity of adverse effects can be increased when Valsartan is combined with Dexmedetomidine. Heparin may increase the hyperkalemic activities of Valsartan. The metabolism of Aminophenazone can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Bendroflumethiazide. The risk or severity of adverse effects can be increased when Valsartan is combined with Dipyridamole. The metabolism of Alprazolam can be decreased when combined with Valsartan. The metabolism of Rosiglitazone can be decreased when combined with Valsartan. The metabolism of Selegiline can be decreased when combined with Valsartan. Barbital may increase the hypotensive activities of Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Etanercept. The metabolism of Doxepin can be decreased when combined with Valsartan. Valsartan may increase the hypotensive activities of Phenoxybenzamine. The metabolism of Ifosfamide can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Sacubitril is combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Icatibant. The metabolism of Valsartan can be decreased when combined with Sulfadiazine. Valsartan may increase the hypotensive activities of Niguldipine. The metabolism of Lornoxicam can be decreased when combined with Valsartan. The metabolism of Rupatadine can be decreased when combined with Valsartan. The metabolism of Phenprocoumon can be decreased when combined with Valsartan. The metabolism of Valsartan can be decreased when combined with Tolbutamide. The metabolism of Loratadine can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Mizoribine. The metabolism of Valsartan can be decreased when combined with Ticagrelor. The risk or severity of adverse effects can be increased when Valsartan is combined with Evening primrose oil. Iproniazid may increase the hypotensive activities of Valsartan. The metabolism of Valsartan can be increased when combined with Primidone. The metabolism of Valsartan can be decreased when combined with Rucaparib. The metabolism of Dextromethorphan can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Clonixin. The risk or severity of adverse effects can be increased when Valsartan is combined with Omapatrilat. The risk or severity of adverse effects can be increased when Valsartan is combined with Balsalazide. The risk or severity of adverse effects can be increased when Imipramine is combined with Valsartan. Valsartan may increase the hypotensive activities of Guanadrel. The metabolism of Pioglitazone can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Pipamperone is combined with Valsartan. The risk or severity of adverse effects can be increased when Ropivacaine is combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Oxyphenbutazone. The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Valsartan. Diazoxide may increase the hypotensive activities of Valsartan. The metabolism of Seratrodast can be decreased when combined with Valsartan. Valsartan may increase the hypotensive activities of Deserpidine. The metabolism of Zaltoprofen can be decreased when combined with Valsartan. The metabolism of Naproxen can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Fenbufen. The risk or severity of adverse effects can be increased when Valsartan is combined with Higenamine. Moxonidine may increase the hypotensive activities of Valsartan. Rasagiline may increase the hypotensive activities of Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Penbutolol. The risk or severity of adverse effects can be increased when Valsartan is combined with Triptolide. Valsartan may increase the hypotensive activities of Tibolone. The risk or severity of adverse effects can be increased when Valsartan is combined with Enalapril. The metabolism of Cabozantinib can be decreased when combined with Valsartan. Valsartan may increase the hypotensive activities of Phentolamine. The risk or severity of adverse effects can be increased when Valsartan is combined with Furosemide. Valsartan may increase the hypotensive activities of Alprenolol. The metabolism of Rofecoxib can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Tolfenamic Acid. The risk or severity of adverse effects can be increased when Valsartan is combined with Imidapril. The metabolism of Mephenytoin can be decreased when combined with Valsartan. Valsartan may increase the hypotensive activities of Cyclopenthiazide. The risk or severity of adverse effects can be increased when Valsartan is combined with Bucillamine. The metabolism of Cinnarizine can be decreased when combined with Valsartan. The metabolism of Mestranol can be decreased when combined with Valsartan. Valsartan may increase the hypotensive activities of Manidipine. The metabolism of Valsartan can be increased when combined with Carbamazepine. Phenoxypropazine may increase the hypotensive activities of Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Betaxolol. The risk or severity of adverse effects can be increased when Valsartan is combined with Papaverine. The metabolism of Terbinafine can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Candoxatril. Iproclozide may increase the hypotensive activities of Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Moexipril. The metabolism of Bortezomib can be decreased when combined with Valsartan. The metabolism of Halothane can be decreased when combined with Valsartan. The metabolism of Epoprostenol can be decreased when combined with Valsartan. Pentoxifylline may increase the hypotensive activities of Valsartan. The metabolism of Valsartan can be increased when combined with Rifampicin. The risk or severity of adverse effects can be increased when Valsartan is combined with Levobunolol. The metabolism of Valsartan can be decreased when combined with Fluvastatin. The risk or severity of adverse effects can be increased when Valsartan is combined with Zofenopril. The risk or severity of adverse effects can be increased when Valsartan is combined with Mecamylamine. The risk or severity of adverse effects can be increased when Valsartan is combined with Nebivolol. The risk or severity of adverse effects can be increased when Valsartan is combined with Diflunisal. Amphetamine may increase the hypotensive activities of Valsartan. Indoramin may increase the hypotensive activities of Valsartan. The metabolism of Moclobemide can be decreased when combined with Valsartan. Trimazosin may increase the hypotensive activities of Valsartan. The metabolism of Chlorpropamide can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Spirapril. The metabolism of Acetylsalicylic acid can be decreased when combined with Valsartan. The metabolism of Licofelone can be decreased when combined with Valsartan. The metabolism of Eletriptan can be decreased when combined with Valsartan. Valsartan may increase the hypotensive activities of Obinutuzumab. The metabolism of Valsartan can be increased when combined with Secobarbital. The metabolism of Ondansetron can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Ropinirole is combined with Valsartan. The metabolism of Testosterone can be decreased when combined with Valsartan. The serum concentration of Lithium can be increased when it is combined with Valsartan. The metabolism of Zopiclone can be decreased when combined with Valsartan. The metabolism of Valsartan can be decreased when combined with Delavirdine. The risk or severity of adverse effects can be increased when Valsartan is combined with Nimesulide. The metabolism of Ixazomib can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Reserpine. The risk or severity of adverse effects can be increased when Valsartan is combined with Eprosartan. Valsartan may increase the hypotensive activities of Mibefradil. The metabolism of Valsartan can be increased when combined with Phenobarbital. Valsartan may increase the hypotensive activities of Polythiazide. The metabolism of Nevirapine can be decreased when combined with Valsartan. Valsartan may increase the hypotensive activities of Lacidipine. The metabolism of Valsartan can be decreased when combined with Fluorouracil. The risk or severity of adverse effects can be increased when Valsartan is combined with Naftifine. Valsartan may increase the arrhythmogenic activities of Ciprofloxacin. Pirlindole may increase the hypotensive activities of Valsartan. The metabolism of Diazepam can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Tizanidine. Valsartan may increase the hypotensive activities of Nilvadipine. Urapidil may increase the hypotensive activities of Valsartan. The metabolism of Dolasetron can be decreased when combined with Valsartan. The metabolism of Valsartan can be increased when combined with Rifapentine. The risk or severity of adverse effects can be increased when Valsartan is combined with Curcumin. The metabolism of Etravirine can be decreased when combined with Valsartan. The metabolism of Bupropion can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Nesiritide. The metabolism of Atazanavir can be decreased when combined with Valsartan. Valsartan may increase the hypotensive activities of Nitrendipine. Dihydralazine may increase the hypotensive activities of Valsartan. Quinine may increase the hypotensive activities of Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Indapamide. The risk or severity of adverse effects can be increased when Valsartan is combined with Triamterene.